目的 系統(tǒng)評價匹多莫德對兒童反復呼吸道感染患者免疫功能的影響，為臨床提供循證醫(yī)學證據(jù)。方法 計算機檢索PubMed、Embase、中國生物醫(yī)學文獻數(shù)據(jù)庫（CBM）、中國知網(wǎng)（CNKI）、維普數(shù)據(jù)庫（VIP）和萬方數(shù)據(jù)庫，收集匹多莫德聯(lián)合常規(guī)治療（試驗組）對比單用常規(guī)治療（對照組）對兒童反復呼吸道感染患者免疫功能水平影響的隨機對照研究（RCT），檢索時間為2000年1月-2018年3月，提取資料并評價質(zhì)量后，采用RevMan 5.2軟件進行Meta-分析。結(jié)果 共納入14篇RCTs，1 287例患兒。Meta-分析結(jié)果顯示試驗組總有效率高于對照組（RR=1.30，95%CI=1.23~1.37，P<0.001），感染復發(fā)次數(shù)小于對照組（MD=-2.41，95%CI=-2.81~-2.01，P<0.001），退熱時間、咳嗽緩解時間和肺部啰音消失時間均小于對照組（P<0.001）；IgA增加值（MD=0.40，95%CI=0.32~0.47，P<0.001）、IgM增加值（MD=0.36，95%CI=0.25~0.48，P<0.001）和IgG增加值（MD=1.39，95%CI=0.85~1.92，P<0.001）均顯著大于對照組；CD3⁺增加值（MD=8.91，95%CI=5.16~12.67，P<0.001）、CD4⁺增加值（MD=5.52，95%CI=2.92~8.11，P<0.001）、CD8⁺增加值（MD=4.52，95%CI=2.21~6.84，P<0.001）和CD4⁺/CD8⁺增加值（MD=0.27，95%CI=0.16~0.39，P<0.001）均顯著大于對照組。結(jié)論 匹多莫德能夠顯著改善兒童RRTI的免疫水平，從而提高總有效率和減少感染復發(fā)次數(shù)。

Objective To evaluate the immune function of pidotimod in children with recurrent respiratory tract infection (RRTI),and provide evidence-based medical evidence for the clinic.Methods The randomized controlled trials of pidotimod combined with conventional treatment (test group) vs conventional treatment (control group) of immune function in children with RRTI were searched from the database including Pubmed,Embase,CNKI,VIP,CBM and Wangfang Data by computer from January 2000 to March 2018.References of included studies were also retrieved.Screened studies according to inclusion and exclusion criteria,extracted valid data,and assessed the methodological quality of including literatures.Meta-analysis was performed using RevMan 5.2 software.Results A Total of 14 RCTs and 1 287 patients were included.Meta-analysis showed that compared with control group,test group improved total effective rate (RR=1.30,95%CI=1.23~1.37,P<0.001),reduced infection recurrence frequency (MD=-2.41,95%CI=-2.81~-2.01,P<0.001),and reduced the time of antipyretic,cough relief and lung snoring disappear,the difference were statistically (P<0.001);meanwhile improved the IgA level (MD=0.40,95%CI=0.32~0.47,P<0.001),improved the IgM level (MD=0.36,95%CI=0.25~0.48,P<0.001) and improved IgG level (MD=1.39,95%CI=0.85~1.92,P<0.001);improved the CD3⁺ level (MD=8.91,95%CI=5.16~12.67,P<0.001),improved the CD4⁺ level (MD=5.52,95%CI=2.92~8.11,P<0.001) and reduced CD8⁺ level (MD=-4.52,95%CI=-6.84~-2.21,P<0.001) and improved CD4⁺/CD8⁺ level (MD=0.27,95%CI=0.16~0.39,P<0.001).Conclusion Pidotimod can significantly improve the immune level of children with RRTI,thereby increasing the total effective rate and reducing the number of infection recurrences.